• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [24038 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Oncotype DX in women and men with ER-positive HER2-negative early stage breast cancer Who are lymph node-positive: a review of clinical effectiveness and guidelines
2014     National Evidence-based Healthcare Collaborating Agency (NECA) [Clinical effectiveness and safety of robotic surgery]
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) The use of the electromotive drug administration system in patients with overactive bladder: a review of the clinical effectiveness, safety, and cost-effectiveness
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Mass thermography screening for infection and prevention: a review of the clinical effectiveness
2014     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Consultation protocol to guide the assessment of foot and ankle services by podiatric surgeons
2014     NIHR Horizon Scanning Centre (NIHR HSC) Idelalisib and ofatumumab for relapsed chronic lymphocytic leukaemia
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Compressible non-articulating disc prostheses in adult patients with degenerative disc disease: clinical effectiveness, safety, cost-effectiveness, and guidelines
2014     National Evidence-based Healthcare Collaborating Agency (NECA) [Decision Making Process for Safety Issues in Health Services and Technologies]
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Botulinum toxin A for myofascial pain syndrome: a review of the clinical effectiveness
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Long-acting beta2-agonists for chronic obstructive pulmonary disease: safety and harms
2014     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Local anaesthetic (LA) nerve blockade for post-surgical analgesia
2014     NIHR Horizon Scanning Centre (NIHR HSC) Etirinotecan pegol for metastatic breast cancer - second or subsequent line
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Smart infusion pump use in hospitalized patients: clinical safety and guidelines
2014     National Evidence-based Healthcare Collaborating Agency (NECA) [A study on the system and execution model for health technology reassessment]
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) The use of the electromotive drug administration system in patients with superficial bladder cancer: a review of the clinical effectiveness, safety, and cost-effectiveness
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Transmission of infectious agents from magazines, books, and toys in healthcare settings: clinical evidence and guidelines
2014     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Vagus nerve stimulation therapy
2014     NIHR Horizon Scanning Centre (NIHR HSC) Cediranib for ovarian cancer – second line
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Intranasal versus intravenous administration of anxiolytic or analgesic medications: comparative clinical effectiveness
2014     National Evidence-based Healthcare Collaborating Agency (NECA) [Study on the introduction of horizon scanning system for emerging health technology]
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Hydroxyethyl starch use for patients with postpartum hemorrhage: a review of clinical effectiveness, safety, and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Implementation of extracorporeal membrane oxygenation: clinical evidence
2014     NIHR Health Technology Assessment programme KRAS mutation testing of tumours in adults with metastatic colorectal cancer: a systematic review and cost-effectiveness analysis
2014     NIHR Horizon Scanning Centre (NIHR HSC) Alisertib for relapsed or refractory peripheral T-cell lymphoma – second and subsequent line
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Intensivist response time to a closed intensive care unit: patient benefits and harms and guidelines
2014     National Evidence-based Healthcare Collaborating Agency (NECA) [The mortality rate and medical costs identified by a national health examination analysis]
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Debridement procedures for managing diabetic foot ulcers: a review of clinical effectiveness, cost-effectiveness, and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Screening tools to identify adults with cognitive impairment associated with dementia: diagnostic accuracy
2014     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Insertion of subcutaneous electrode for the purpose of use with an implantable cardioverter defibrillator (ICD)
2014     NIHR Horizon Scanning Centre (NIHR HSC) Cholic acid (Orphacol) for inborn errors of primary bile acid synthesis – first line
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) TECNIS® or Acrysof® soft intraocular lenses for patients undergoing cataract surgery: benefits and harms, clinical effectiveness, cost-effectiveness, and guidelines
2014     National Evidence-based Healthcare Collaborating Agency (NECA) [Priority setting of clinical preventive services for benefits extension]
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Nabilone for non-chemotherapy-associated nausea and weight loss due to medical conditions: a review of the clinical effectiveness and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Treatment strategies for patients with renal colic: a review of the comparative clinical and cost-effectiveness
2014     NIHR Horizon Scanning Centre (NIHR HSC) Migalastat for Fabry disease: update
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Wireless device use and patient monitoring equipment in any healthcare delivery setting: a review of safety and guidelines
2014     National Evidence-based Healthcare Collaborating Agency (NECA) [Cost-effectiveness of conventional cytology and HPV DNA testing for cervical cancer screening in South Korea]
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Drug therapy for chronic thromboembolic pulmonary hypertension: a review of the comparative clinical effectiveness
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Treatments for constipation: a review of systematic reviews
2014     NIHR Horizon Scanning Centre (NIHR HSC) Denosumab for glucocorticoid-induced osteoporosis
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Montelukast for sleep apnea: a review of the clinical effectiveness, cost effectiveness, and guidelines
2014     National Evidence-based Healthcare Collaborating Agency (NECA) [Diagnostic usefulness of brain FDG-PET for Alzheimer's dementia]
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Infection prevention and control procedures for carbapenemase-producing Enterobacteriaceae: clinical effectiveness and guidelines
2014     NIHR Horizon Scanning Centre (NIHR HSC) Perampanel for adjuvant treatment of primary generalised tonic-clonic seizures
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Nicotine replacement therapy for smoking cessation or reduction: a review of the clinical evidence
2014     National Evidence-based Healthcare Collaborating Agency (NECA) [Comparative effectiveness of medication therapies in the rheumatoid arthritis patients]
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Acyclovir versus valacyclovir for herpes virus in children and pregnant women: a review of the clinical evidence and guidelines
2014     NIHR Horizon Scanning Centre (NIHR HSC) Daclatasvir and sofosbuvir (Sovaldi) with and without ribavirin for chronic hepatitis C infection
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Dexmedetomidine for sedation of patients in the ICU or PICU: review of clinical effectiveness and safety
2014     National Evidence-based Healthcare Collaborating Agency (NECA) [Health Technology Assessment on diagnostic testing: Cardiac MRI and MRSA genetic testing (Real-time polymerase chain reaction)]
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Obstetric, neonatal, and child outcomes for women with previous bariatric surgery: a review of the clinical evidence
2014     Institute for Clinical and Economic Review (ICER) Appropriate imaging for breast cancer screening in special populations
2014     NIHR Horizon Scanning Centre (NIHR HSC) Tofacitinib for moderate to severe active ulcerative colitis
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Saxagliptin (Onglyza - Bristol-Myers Squibb/AstraZeneca Canada Inc.) indication: type 2 diabetes mellitus
2014     Agency for Healthcare Research and Quality (AHRQ) Imaging techniques for treatment evaluation for metastatic breast cancer
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Essential oil products for disinfection: clinical effectiveness, cost-effectiveness, and guidelines
2014     Institute for Clinical and Economic Review (ICER) Proton beam therapy
2014     Scottish Health Technologies Group (SHTG) Transcatheter aortic valve implantation (TAVI) for severe symptomatic aortic stenosis in adults at high surgical risk
2014     NIHR Horizon Scanning Centre (NIHR HSC) Ixazomib in combination with oral dexamethasone for relapsed or refractory systemic light chain (AL) amyloidosis
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Clinical review report. Saxagliptin (Onglyza - Bristol-Myers Squibb/AstraZeneca Canada Inc.) indication: type 2 diabetes mellitus
2014     Agency for Healthcare Research and Quality (AHRQ) The effectiveness and risks of long-term opioid treatment of chronic pain
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Pharmacoeconomic review report. Sofosbuvir (Sovaldi — Gilead Sciences Canada, Inc.) indication: chronic hepatitis C infection
2014     Scottish Health Technologies Group (SHTG) Transcatheter aortic valve implantation (TAVI) for severe symptomatic aortic stenosis in adults who are not eligible for surgery
2014     NIHR Horizon Scanning Centre (NIHR HSC) Levosimendan (Leximda) for severe acute decompensated chronic heart failure – second line
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Pharmacoeconomic review report. Saxagliptin (Onglyza - Bristol-Myers Squibb/AstraZeneca Canada Inc.) indication: type 2 diabetes mellitus
2014     Agency for Healthcare Research and Quality (AHRQ) Imaging tests for the diagnosis and staging of pancreatic adenocarcinoma
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Clinical review report. Sofosbuvir (Sovaldi — Gilead Sciences Canada, Inc.) indication: chronic hepatitis C infection
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Ulipristal Acetate (Fibristal - Actavis Specialty Pharmaceuticals Co.) indication: uterine fibroids
2014     Agency for Healthcare Research and Quality (AHRQ) Chronic urinary retention: comparative effectiveness and harms of treatments.
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Sofosbuvir (Sovaldi — Gilead Sciences Canada, Inc.) indication: chronic hepatitis C infection
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Pharmacoeconomic review report. Ulipristal Acetate (Fibristal - Actavis Specialty Pharmaceuticals Co.) indication: uterine fibroids
2014     Agency for Healthcare Research and Quality (AHRQ) Vitamin D and calcium: a systematic review of health outcomes (update)
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Aripiprazole (Abilify — Bristol-Myers Squibb Canada) new indication: major depressive disorder
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Clinical review report. Ulipristal Acetate (Fibristal - Actavis Specialty Pharmaceuticals Co.) indication: uterine fibroids
2014     Agency for Healthcare Research and Quality (AHRQ) Imaging tests for the staging of colorectal cancer
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Ustekinumab (Stelara — Janssen Inc.) indication: psoriatic arthritis
2014     Scottish Health Technologies Group (SHTG) Are homeopathic remedies clinically and cost effective in the treatment of migraine and osteoarthritis?
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Subsequent entry biologics — emerging trends in regulatory and health technology assessment frameworks
2014     Agency for Healthcare Research and Quality (AHRQ) The empirical evidence of bias in trials measuring treatment differences
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Aflibercept (Eylea — Bayer Inc.) indication: wet age-related macular degeneration
2014     NIHR Health Technology Assessment programme Adenoidectomy with or without grommets for children with otitis media: an individual patient data meta-analysis
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Goal setting tools for children: clinical effectiveness and guidelines
2014     Agency for Healthcare Research and Quality (AHRQ) Linking data for health services research: a framework and instructional guide
2014     University of York Evidence to inform urgent and emergency care systems
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Stiripentol (Diacomit — Biocodex SA) indication: severe myoclonic epilepsy in infancy (Dravet syndrome)
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Maxillary artery ligation for the treatment of cluster or migraine headaches: clinical effectiveness and guidelines
2014     Agency for Healthcare Research and Quality (AHRQ) Core needle and open surgical biopsy for diagnosis of breast lesions: an update to the 2009 report
2014     University of York Interventions for loneliness and social isolation
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Clinical review report. Teriflunomide (Aubagio — Genzyme Canada) indication: relapsing-remitting multiple sclerosis
2014     NIHR Health Technology Assessment programme Effectiveness and cost-effectiveness of traditional and new partner notification technologies for curable sexually transmitted infections: observational study, systematic reviews and mathematical modelling
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Hemodialysis chairs versus beds for patients at out-patient clinics: clinical evidence
2014     Belgian Health Care Knowledge Centre (KCE) A quadrivalent vaccine against serogroup B meningococcal disease: a cost-effectiveness study
2014     University of York Self-care support for people with COPD
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Pharmacoeconomic review report. Teriflunomide (Aubagio — Genzyme Canada) indication: relapsing-remitting multiple sclerosis
2014     NIHR Horizon Scanning Centre (NIHR HSC) BreathLink™ for breast cancer screening
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Computed tomography-guided brachytherapy treatment in the operating room: clinical effectiveness, cost-effectiveness, and guidelines
2014     Belgian Health Care Knowledge Centre (KCE) The long-term efficacy of psychotherapy, alone or in combination with antidepressants, in the treatment of adult major depression.
2014     University of York Predictive validity of tools used to assess the risk of unplanned admissions: A rapid review of the evidence.
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Teriflunomide (Aubagio — Genzyme Canada) indication: relapsing-remitting multiple sclerosis
2014     NIHR Horizon Scanning Centre (NIHR HSC) The ViewRay™ System for MRI-guided radiotherapy